![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and ...
Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting Qelbree’s multimodal pharmacodynamics Qelbree is the first ADHD treatment to meet its post …